Iron and Alzheimer's disease: From pathogenesis to therapeutic implications

Frontiers in Neuroscience

Volumn 12, Issue SEP, 2018, Pages

  Liu, Jun Lin ^a   Fan, Yong Gang ^a   Yang, Zheng Sheng ^b   Wang, Zhan You ^a,c   Guo, Chuang ^a  

^a NORTHEASTERN UNIVERSITY   (China)

^b FIRST HOSPITAL OF QINHUANGDAO   (China)

^c CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Alpha lipoic acid; Alzheimer's disease; Chelation; Iron; Lactoferrin

Indexed keywords

AMYLOID BETA PROTEIN; CLIOQUINOL; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERROPORTIN 1; IRON; LACTOFERRIN; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; THIOCTIC ACID; TRANSFERRIN; TRANSFERRIN RECEPTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; FERROPTOSIS; HISTOPATHOLOGY; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON DEFICIENCY; IRON HOMEOSTASIS; IRON RESTRICTION; IRON STORAGE; IRON TRANSPORT; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PROTEIN AGGREGATION; REVIEW; TREATMENT PLANNING;

EID: 85053145162     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2018.00632     Document Type: Review

References (164)

1. Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., and Liddell, J. R. (2018). Targeting Nrf2 to suppress ferroptosis and mitochondrial dysfunction in neurodegeneration. Front. Neurosci. 12:466. doi: 10.3389/fnins.2018.00466
2. Aizawa, S., Hoki, M., and Yamamuro, Y. (2017). Lactoferrin promotes autophagy via AMP-activated protein kinase activation through low-density lipoprotein receptor-related protein 1. Biochem. Biophys. Res. Commun. 493, 509-513. doi: 10.1016/j.bbrc.2017.08.160
3. Aliaga, M. E., Carrasco-Pozo, C., Lopez-Alarcon, C., Olea-Azar, C., and Speisky, H. (2011). Superoxide-dependent reduction of free Fe(3+) and release of Fe(2+) from ferritin by the physiologically-occurring Cu(I)-glutathione complex. Bioorg. Med. Chem. 19, 534-541. doi: 10.1016/j.bmc.2010.10.064
4. Alzheimer's Association (2016). 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 12, 459-509
5. Amit, T., Avramovich-Tirosh, Y., Youdim, M. B., and Mandel, S. (2008). Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 22, 1296-1305. doi: 10.1096/fj.07-8627rev
6. Arivazhagan, P., Shila, S., Kumaran, S., and Panneerselvam, C. (2002). Effect of DL-alpha-lipoic acid on the status of lipid peroxidation and antioxidant enzymes in various brain regions of aged rats. Exp. Gerontol. 37, 803-811. doi: 10.1016/S0531-5565(02)00015-3
7. Ayton, S., Diouf, I., Bush, A. I., and Alzheimer's disease Neuroimaging Initiative (2018). Evidence that iron accelerates Alzheimer's pathology: a CSF biomarker study. J. Neurol. Neurosurg. Psychiatry 89, 456-460. doi: 10.1136/jnnp-2017-316551
8. Ayton, S., Faux, N. G., Bush, A. I., and Alzheimer's Disease Neuroimaging Initiative (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. Nat. Commun. 6:6760. doi: 10.1038/ncomms7760
9. Ayton, S., Fazlollahi, A., Bourgeat, P., Raniga, P., Ng, A., Lim, Y. Y., et al. (2017). Cerebral quantitative susceptibility mapping predicts amyloid-beta-related cognitive decline. Brain 140, 2112-2119. doi: 10.1093/brain/awx137
10. Ayton, S., James, S. A., and Bush, A. I. (2017). Nanoscale imaging reveals big role for iron in Alzheimer's disease. Cell Chem. Biol. 24, 1192-1194. doi: 10.1016/j.chembiol.2017.10.002
11. Balejcikova, L., Siposova, K., Kopcansky, P., and Safarik, I. (2018). Fe(II) formation after interaction of the amyloid beta-peptide with iron-storage protein ferritin. J. Biol. Phys. doi: 10.1007/s10867-018-9498-3 [Epub ahead of print]
12. Banerjee, P., Sahoo, A., Anand, S., Ganguly, A., Righi, G., Bovicelli, P., et al. (2014). Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: protective action of negletein. Neuromolecular Med. 16, 787-798. doi: 10.1007/s12017-014-8328-4
13. Belaidi, A. A., and Bush, A. I. (2016). Iron neurochemistry in Alzheimer's disease and Parkinson's disease: targets for therapeutics. J. Neurochem. 139(Suppl. 1), 179-197. doi: 10.1111/jnc.13425
14. Bierhaus, A., Chevion, S., Chevion, M., Hofmann, M., Quehenberger, P., Illmer, T., et al. (1997). Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells. Diabetes Metab. Res. Rev. 46, 1481-1490. doi: 10.2337/diabetes.46.9.1481
15. Billings, J. L., Hare, D. J., Nurjono, M., Volitakis, I., Cherny, R. A., Bush, A. I., et al. (2016). Effects of neonatal iron feeding and chronic clioquinol administration on the parkinsonian human A53T transgenic mouse. ACS Chem. Neurosci. 7, 360-366. doi: 10.1021/acschemneuro.5b00305
16. Blennow, K., De Leon, M. J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403. doi: 10.1016/S0140-6736(06)69113-7
17. Boddaert, N., Le Quan Sang, K. H., Rotig, A., Leroy-Willig, A., Gallet, S., Brunelle, F., et al. (2007). Selective iron chelation in Friedreich ataxia: biologic and clinical implications. Blood 110, 401-408. doi: 10.1182/blood-2006-12-065433
18. Bodovitz, S., Falduto, M. T., Frail, D. E., and Klein, W. L. (1995). Iron levels modulate alpha-secretase cleavage of amyloid precursor protein. J. Neurochem. 64, 307-315. doi: 10.1046/j.1471-4159.1995.64010307.x
19. Boopathi, S., and Kolandaivel, P. (2016). Fe(2+) binding on amyloid beta-peptide promotes aggregation. Proteins 84, 1257-1274. doi: 10.1002/prot.25075
20. Borgna-Pignatti, C., and Marsella, M. (2015). Iron chelation in thalassemia major. Clin. Ther. 37, 2866-2877. doi: 10.1016/j.clinthera.2015.10.001
21. Brown, R. D., Rickard, K. A., and Kronenberg, H. (1985). Lactoferrin in the myeloproliferative disorders: a search for granulopoietic regulator defects. Br. J. Haematol. 59, 617-626. doi: 10.1111/j.1365-2141.1985.tb07356.x
22. Bulk, M., Abdelmoula, W. M., Nabuurs, R. J. A., Van Der Graaf, L. M., Mulders, C. W. H., Mulder, A. A., et al. (2018). Postmortem MRI and histology demonstrate differential iron accumulation and cortical myelin organization in early-and late-onset Alzheimer's disease. Neurobiol. Aging 62, 231-242. doi: 10.1016/j.neurobiolaging.2017.10.017
23. Bush, A. I. (2013). The metal theory of Alzheimer's disease. J. Alzheimers Dis. 33(Suppl. 1), S277-S281. doi: 10.3233/JAD-2012-129011
24. Cahill, C. M., Lahiri, D. K., Huang, X., and Rogers, J. T. (2009). Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim. Biophys. Acta 1790, 615-628. doi: 10.1016/j.bbagen.2008.12.001
25. Callaghan, M. F., Freund, P., Draganski, B., Anderson, E., Cappelletti, M., Chowdhury, R., et al. (2014). Widespread age-related differences in the human brain microstructure revealed by quantitative magnetic resonance imaging. Neurobiol. Aging 35, 1862-1872. doi: 10.1016/j.neurobiolaging.2014.02.008
26. Campbell, A., and Bondy, S. C. (2000). Aluminum induced oxidative events and its relation to inflammation: a role for the metal in Alzheimer's disease. Cell. Mol. Biol. 46, 721-730
27. Cardenas-Aguayo Mdel, C., Gomez-Virgilio, L., Derosa, S., and Meraz-Rios, M. A. (2014). The role of tau oligomers in the onset of Alzheimer's disease neuropathology. ACS Chem. Neurosci. 5, 1178-1191. doi: 10.1021/cn500148z
28. Chen, L., Hambright, W. S., Na, R., and Ran, Q. (2015). Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J. Biol. Chem. 290, 28097-28106. doi: 10.1074/jbc.M115.680090
29. Chen, Y. T., Chen, W. Y., Huang, X. T., Xu, Y. C., and Zhang, H. Y. (2018). Iron dysregulates APP processing accompanying with sAPPalpha cellular retention and beta-secretase inhibition in rat cortical neurons. Acta Pharmacol. Sin. 39, 177-183. doi: 10.1038/aps.2017.113
30. Cheng, X. S., Zhao, K. P., Jiang, X., Du, L. L., Li, X. H., Ma, Z. W., et al. (2013). Nmnat2 attenuates Tau phosphorylation through activation of PP2A. J. Alzheimers Dis. 36, 185-195. doi: 10.3233/JAD-122173
31. Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., Mclean, C. A., et al. (2001). Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676. doi: 10.1016/S0896-6273(01)00317-8
32. Chng, H. T., New, L. S., Neo, A. H., Goh, C. W., Browne, E. R., and Chan, E. C. (2009). Distribution study of orally administered lipoic acid in rat brain tissues. Brain Res. 1251, 80-86. doi: 10.1016/j.brainres.2008.11.025
33. Cohen, S. I., Linse, S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., et al. (2013). Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl. Acad. Sci. U.S.A. 110, 9758-9763. doi: 10.1073/pnas.1218402110
34. Collingwood, J. F., and Davidson, M. R. (2014). The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Front. Pharmacol. 5:191. doi: 10.3389/fphar.2014.00191
35. Colvez, A., Joel, M. E., Ponton-Sanchez, A., and Royer, A. C. (2002). Health status and work burden of Alzheimer patients' informal caregivers: comparisons of five different care programs in the European Union. Health Policy 60, 219-233. doi: 10.1016/S0168-8510(01)00215-9
36. Connor, J. R., Snyder, B. S., Arosio, P., Loeffler, D. A., and Lewitt, P. (1995). A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J. Neurochem. 65, 717-724. doi: 10.1046/j.1471-4159.1995.65020717.x
37. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C. Jr., Rimmler, J. B., et al. (1995). Apolipoprotein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease. Neurology 45, 1323-1328. doi: 10.1212/WNL.45.7.1323
38. Crapper McLachlan, D. R., Dalton, A. J., Kruck, T. P., Bell, M. Y., Smith, W. L., Kalow, W., et al. (1991). Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337, 1304-1308. doi: 10.1016/0140-6736(91)92978-B
39. Crielaard, B. J., Lammers, T., and Rivella, S. (2017). Targeting iron metabolism in drug discovery and delivery. Nat. Rev. Drug Discov. 16, 400-423. doi: 10.1038/nrd.2016.248
40. Cuajungco, M. P., Faget, K. Y., Huang, X., Tanzi, R. E., and Bush, A. I. (2000). Metal chelation as a potential therapy for Alzheimer's disease. Ann. N. Y. Acad. Sci. 920, 292-304. doi: 10.1111/j.1749-6632.2000.tb06938.x
41. Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K., and Perry, V. H. (2005). Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 25, 9275-9284. doi: 10.1523/JNEUROSCI.2614-05.2005
42. Daher, R., Manceau, H., and Karim, Z. (2017). Iron metabolism and the role of the iron-regulating hormone hepcidin in health and disease. Presse Med. 46(12 Pt 2), e272-e278. doi: 10.1016/j.lpm.2017.10.006
43. Dahms, S. O., Konnig, I., Roeser, D., Guhrs, K. H., Mayer, M. C., Kaden, D., et al. (2012). Metal binding dictates conformation and function of the amyloid precursor protein (APP) E2 domain. J. Mol. Biol. 416, 438-452. doi: 10.1016/j.jmb.2011.12.057
44. De Domenico, I., Nemeth, E., Nelson, J. M., Phillips, J. D., Ajioka, R. S., Kay, M. S., et al. (2008). The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab. 8, 146-156. doi: 10.1016/j.cmet.2008.07.002
45. de Freitas, R. M. (2010). Lipoic acid increases hippocampal choline acetyltransferase and acetylcholinesterase activities and improvement memory in epileptic rats. Neurochem. Res. 35, 162-170. doi: 10.1007/s11064-009-0041-6
46. Dhennin-Duthille, I., Masson, M., Damiens, E., Fillebeen, C., Spik, G., and Mazurier, J. (2000). Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J. Cell. Biochem. 79, 583-593. doi: 10.1002/1097-4644(20001215)79:4<583::AID-JCB70>3.0.CO;2-9
47. Dixon, S. J. (2017). Ferroptosis: bug or feature? Immunol. Rev. 277, 150-157. doi: 10.1111/imr.12533
48. Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072. doi: 10.1016/j.cell.2012.03.042
49. Dringen, R., Bishop, G. M., Koeppe, M., Dang, T. N., and Robinson, S. R. (2007). The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem. Res. 32, 1884-1890. doi: 10.1007/s11064-007-9375-0
50. Du, F., Qian, C., Qian, Z. M., Wu, X. M., Xie, H., Yung, W. H., et al. (2011). Hepcidin directly inhibits transferrin receptor 1 expression in astrocytes via a cyclic AMP-protein kinase A pathway. Glia 59, 936-945. doi: 10.1002/glia.21166
51. Du, F., Qian, Z. M., Luo, Q., Yung, W. H., and Ke, Y. (2015). Hepcidin suppresses brain iron accumulation by downregulating iron transport proteins in iron-overloaded rats. Mol. Neurobiol. 52, 101-114. doi: 10.1007/s12035-014-8847-x
52. Du, L., Zhao, Z., Cui, A., Zhu, Y., Zhang, L., Liu, J., et al. (2018). increased iron deposition on brain quantitative susceptibility mapping correlates with decreased cognitive function in Alzheimer's disease. ACS Chem. Neurosci. 9, 1849-1857. doi: 10.1021/acschemneuro.8b00194
53. Duce, J. A., Tsatsanis, A., Cater, M. A., James, S. A., Robb, E., Wikhe, K., et al. (2010). Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142, 857-867. doi: 10.1016/j.cell.2010.08.014
54. Dusek, P., Schneider, S. A., and Aaseth, J. (2016). Iron chelation in the treatment of neurodegenerative diseases. J. Trace Elem. Med. Biol. 38, 81-92. doi: 10.1016/j.jtemb.2016.03.010
55. Dwivedi, N., Flora, G., Kushwaha, P., and Flora, S. J. (2014). Alpha-lipoic acid protects oxidative stress, changes in cholinergic system and tissue histopathology during co-exposure to arsenic-dichlorvos in rats. Environ. Toxicol. Pharmacol. 37, 7-23. doi: 10.1016/j.etap.2013.10.010
56. Dwyer, B. E., Zacharski, L. R., Balestra, D. J., Lerner, A. J., Perry, G., Zhu, X., et al. (2009). Getting the iron out: phlebotomy for Alzheimer's disease? Med. Hypotheses 72, 504-509. doi: 10.1016/j.mehy.2008.12.029
57. Everett, J., Cespedes, E., Shelford, L. R., Exley, C., Collingwood, J. F., Dobson, J., et al. (2014). Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide beta-amyloid (1-42). J. R. Soc. Interface 11:20140165. doi: 10.1098/rsif.2014.0165
58. Everett, J., Collingwood, J. F., Tjendana-Tjhin, V., Brooks, J., Lermyte, F., Plascencia-Villa, G., et al. (2018). Nanoscale synchrotron X-ray speciation of iron and calcium compounds in amyloid plaque cores from Alzheimer's disease subjects. Nanoscale 10, 11782-11796. doi: 10.1039/c7nr06794a
59. Fava, A., Pirritano, D., Plastino, M., Cristiano, D., Puccio, G., Colica, C., et al. (2013). The effect of lipoic acid therapy on cognitive functioning in patients with Alzheimer's disease. J. Neurodegener. Dis. 2013, 454253. doi: 10.1155/2013/454253
60. Fine, J. M., Baillargeon, A. M., Renner, D. B., Hoerster, N. S., Tokarev, J., Colton, S., et al. (2012). Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1alpha, and phosphorylates GSK3beta in P301L tau transgenic mice. Exp. Brain Res. 219, 381-390. doi: 10.1007/s00221-012-3101-0
61. Fonte, J., Miklossy, J., Atwood, C., and Martins, R. (2001). The severity of cortical Alzheimer's type changes is positively correlated with increased amyloid-β Levels: Resolubilization of amyloid-β with transition metal ion chelators. J. Alzheimers Dis. 3, 209-219. doi: 10.3233/JAD-2001-3206
62. Frazer, D. M., and Anderson, G. J. (2005). Iron imports. I. Intestinal iron absorption and its regulation. Am. J. Physiol. Gastrointest. Liver Physiol. 289, G631-G635. doi: 10.1152/ajpgi.00220.2005
63. Galante, D., Cavallo, E., Perico, A., and D'arrigo, C. (2018). Effect of ferric citrate on amyloid-beta peptides behavior. Biopolymers 109:e23224. doi: 10.1002/bip.23224
64. Gao, M., Monian, P., Pan, Q., Zhang, W., Xiang, J., and Jiang, X. (2016). Ferroptosis is an autophagic cell death process. Cell Res. 26, 1021-1032. doi: 10.1038/cr.2016.95
65. Garrick, M. D., and Garrick, L. M. (2009). Cellular iron transport. Biochim. Biophys. Acta 1790, 309-325. doi: 10.1016/j.bbagen.2009.03.018
66. Gerlach, M., Ben-Shachar, D., Riederer, P., and Youdim, M. B. (1994). Altered brain metabolism of iron as a cause of neurodegenerative diseases? J. Neurochem. 63, 793-807. doi: 10.1046/j.1471-4159.1994.63030793.x
67. Giampietro, R., Spinelli, F., Contino, M., and Colabufo, N. A. (2018). The pivotal role of copper in neurodegeneration: a new strategy for the therapy of neurodegenerative disorders. Mol. Pharm. 15, 808-820. doi: 10.1021/acs.molpharmaceut.7b00841
68. Goodman, L. (1953). Alzheimer's disease; a clinico-pathologic analysis of twenty-three cases with a theory on pathogenesis. J. Nerv. Ment. Dis. 118, 97-130. doi: 10.1097/00005053-195308000-00001
69. Goozee, K., Chatterjee, P., James, I., Shen, K., Sohrabi, H. R., Asih, P. R., et al. (2017). Elevated plasma ferritin in elderly individuals with high neocortical amyloid-beta load. Mol. Psychiatry doi: 10.1038/mp.2017.146 [Epub ahead of print]
70. Goralska, M., Dackor, R., Holley, B., and Mcgahan, M. C. (2003). Alpha lipoic acid changes iron uptake and storage in lens epithelial cells. Exp. Eye Res. 76, 241-248. doi: 10.1016/S0014-4835(02)00307-X
71. Grossi, C., Francese, S., Casini, A., Rosi, M. C., Luccarini, I., Fiorentini, A., et al. (2009). Clioquinol decreases amyloid-beta burden and reduces working memory impairment in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis. 17, 423-440. doi: 10.3233/JAD-2009-1063
72. Guerreiro, C., Silva, B., Crespo, A. C., Marques, L., Costa, S., Timoteo, A., et al. (2015). Decrease in APP and CP mRNA expression supports impairment of iron export in Alzheimer's disease patients. Biochim. Biophys. Acta 1852, 2116-2122. doi: 10.1016/j.bbadis.2015.07.017
73. Guo, C., Wang, P., Zhong, M. L., Wang, T., Huang, X. S., Li, J. Y., et al. (2013). Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 62, 165-172. doi: 10.1016/j.neuint.2012.12.005
74. Guo, C., Wang, T., Zheng, W., Shan, Z. Y., Teng, W. P., and Wang, Z. Y. (2013). Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease. Neurobiol. Aging 34, 562-575. doi: 10.1016/j.neurobiolaging.2012.05.009
75. Guo, C., Yang, Z. H., Zhang, S., Chai, R., Xue, H., Zhang, Y. H., et al. (2017). Intranasal lactoferrin enhances alpha-secretase-dependent amyloid precursor protein processing via the ERK1/2-CREB and HIF-1alpha pathways in an Alzheimer's disease mouse model. Neuropsychopharmacology 42, 2504-2515. doi: 10.1038/npp.2017.8
76. Guo, C., Zhang, Y. X., Wang, T., Zhong, M. L., Yang, Z. H., Hao, L. J., et al. (2015). Intranasal deferoxamine attenuates synapse loss via up-regulating the P38/HIF-1alpha pathway on the brain of APP/PS1 transgenic mice. Front. Aging Neurosci. 7:104. doi: 10.3389/fnagi.2015.00104
77. Guo, J., Gao, S., Liu, Z., Zhao, R., and Yang, X. (2016). Alpha-lipoic acid alleviates acute inflammation and promotes lipid mobilization during the inflammatory response in white adipose tissue of mice. Lipids 51, 1145-1152. doi: 10.1007/s11745-016-4185-2
78. Ha, C., Ryu, J., and Park, C. B. (2007). Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry 46, 6118-6125. doi: 10.1021/bi7000032
79. Hambright, W. S., Fonseca, R. S., Chen, L., Na, R., and Ran, Q. (2017). Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 12, 8-17. doi: 10.1016/j.redox.2017.01.021
80. Hirata, Y., Yamada, C., Ito, Y., Yamamoto, S., Nagase, H., Oh-Hashi, K., et al. (2018). Novel oxindole derivatives prevent oxidative stress-induced cell death in mouse hippocampal HT22cells. Neuropharmacology 135, 242-252. doi: 10.1016/j.neuropharm.2018.03.015
81. Hohenberger, J., Ray, K., and Meyer, K. (2012). The biology and chemistry of high-valent iron-oxo and iron-nitrido complexes. Nat. Commun. 3:720. doi: 10.1038/ncomms1718
82. Horl, W. H. (2008). New insights into intestinal iron absorption. Nephrol. Dial. Transplant. 23, 3063-3064. doi: 10.1093/ndt/gfn458
83. House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., and Exley, C. (2004). Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 6, 291-301. doi: 10.3233/JAD-2004-6310
84. Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222. doi: 10.1016/j.cell.2012.02.040
85. Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Wuu, J., Mathis, C. A., Scheff, S. W., et al. (2011). Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease. Neurology 77, 39-47. doi: 10.1212/WNL.0b013e3182231419
86. Kamalinia, G., Khodagholi, F., Atyabi, F., Amini, M., Shaerzadeh, F., Sharifzadeh, M., et al. (2013). Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies. Mol. Pharm. 10, 4418-4431. doi: 10.1021/mp4002014
87. Kawahara, M., Kato-Negishi, M., and Tanaka, K. (2017). Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases. Metallomics 9, 619-633. doi: 10.1039/c7mt00046d
88. Kawahara, M., Tanaka, K. I., and Kato-Negishi, M. (2018). Zinc, carnosine, and neurodegenerative diseases. Nutrients 10:E147. doi: 10.3390/nu10020147
89. Kawamata, T., Tooyama, I., Yamada, T., Walker, D. G., and Mcgeer, P. L. (1993). Lactotransferrin immunocytochemistry in Alzheimer and normal human brain. Am. J. Pathol. 142, 1574-1585
90. Ke, Y., and Qian, Z. M. (2007). Brain iron metabolism: neurobiology and neurochemistry. Prog. Neurobiol. 83, 149-173. doi: 10.1016/j.pneurobio.2007.07.009
91. Kim, A. C., Lim, S., and Kim, Y. K. (2018). Metal ion effects on abeta and tau aggregation. Int. J. Mol. Sci. 19:128. doi: 10.3390/ijms19010128
92. Klein, W. L., Krafft, G. A., and Finch, C. E. (2001). Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24,219-224
93. Krishnamurthy, P., Xie, T., and Schuetz, J. D. (2007). The role of transporters in cellular heme and porphyrin homeostasis. Pharmacol. Ther. 114, 345-358. doi: 10.1016/j.pharmthera.2007.02.001
94. Kudin, A. P., Bimpong-Buta, N. Y., Vielhaber, S., Elger, C. E., and Kunz, W. S. (2004). Characterization of superoxide-producing sites in isolated brain mitochondria. J. Biol. Chem. 279, 4127-4135. doi: 10.1074/jbc.M310341200
95. Kummer, M. P., Hermes, M., Delekarte, A., Hammerschmidt, T., Kumar, S., Terwel, D., et al. (2011). Nitration of tyrosine 10 critically enhances amyloid beta aggregation and plaque formation. Neuron 71, 833-844. doi: 10.1016/j.neuron.2011.07.001
96. Kunt, T., Forst, T., Wilhelm, A., Tritschler, H., Pfuetzner, A., Harzer, O., et al. (1999). Alpha-lipoic acid reduces expression of vascular cell adhesion molecule-1 and endothelial adhesion of human monocytes after stimulation with advanced glycation end products. Clin. Sci. 96, 75-82. doi: 10.1042/cs0960075
97. Lane, D. J. R., Ayton, S., and Bush, A. I. (2018). Iron and Alzheimer's disease: an update on emerging mechanisms. J. Alzheimers Dis. 64, S379-S395. doi: 10.3233/JAD-179944
98. Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., et al. (2015). Clioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse. Neurobiol. Dis. 81, 168-175. doi: 10.1016/j.nbd.2015.03.015
99. Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., et al. (2012). Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export. Nat. Med. 18, 291-295. doi: 10.1038/nm.2613
100. Li, X., Lei, P., Tuo, Q., Ayton, S., Li, Q. X., Moon, S., et al. (2015). Enduring elevations of hippocampal amyloid precursor protein and iron are features of beta-amyloid toxicity and are mediated by Tau. Neurotherapeutics 12, 862-873. doi: 10.1007/s13311-015-0378-2
101. Li, X., Liu, Y., Zheng, Q., Yao, G., Cheng, P., Bu, G., et al. (2013). Ferritin light chain interacts with PEN-2 and affects gamma-secretase activity. Neurosci. Lett. 548, 90-94. doi: 10.1016/j.neulet.2013.05.018
102. Liu, G., Huang, W., Moir, R. D., Vanderburg, C. R., Lai, B., Peng, Z., et al. (2006). Metal exposure and Alzheimer's pathogenesis. J. Struct. Biol. 155, 45-51. doi: 10.1016/j.jsb.2005.12.011
103. Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., and Markesbery, W. R. (1998). Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52. doi: 10.1016/S0022-510X(98)00092-6
104. May, P. M., and Bulman, R. A. (1983). The present status of chelating agents in medicine. Prog. Med. Chem. 20, 225-336. doi: 10.1016/S0079-6468(08)70220-0
105. Mena, N. P., Urrutia, P. J., Lourido, F., Carrasco, C. M., and Nunez, M. T. (2015). Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders. Mitochondrion 21, 92-105. doi: 10.1016/j.mito.2015.02.001
106. Metz-Boutigue, M. H., Jolles, J., Mazurier, J., Schoentgen, F., Legrand, D., Spik, G., et al. (1984). Human lactotransferrin: amino acid sequence and structural comparisons with other transferrins. Eur. J. Biochem. 145, 659-676. doi: 10.1111/j.1432-1033.1984.tb08607.x
107. Moon, Y., Han, S. H., and Moon, W. J. (2016). Patterns of brain iron accumulation in vascular dementia and Alzheimer's dementia using quantitative susceptibility mapping imaging. J. Alzheimers Dis. 51, 737-745. doi: 10.3233/JAD-151037
108. Morse, L. J., Payton, S. M., Cuny, G. D., and Rogers, J. T. (2004). FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J. Mol. Neurosci. 24, 129-136. doi: 10.1385/JMN:24:1:129
109. Mullard, A. (2012). Sting of Alzheimer's failures offset by upcoming prevention trials. Nat. Rev. Drug Discov. 11, 657-660. doi: 10.1038/nrd3842
110. Myhre, O., Utkilen, H., Duale, N., Brunborg, G., and Hofer, T. (2013). Metal dyshomeostasis and inflammation in Alzheimer's and Parkinson's diseases: possible impact of environmental exposures. Oxid. Med. Cell. Longev. 2013:726954. doi: 10.1155/2013/726954
111. Nakamura, T., and Lipton, S. A. (2011). S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid. Redox. Signal. 14, 1479-1492. doi: 10.1089/ars.2010.3570
112. Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., et al. (2001). Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60, 759-767. doi: 10.1093/jnen/60.8.759
113. O'Callaghan, J., Holmes, H., Powell, N., Wells, J. A., Ismail, O., Harrison, I. F., et al. (2017). Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease. Neuroimage 159, 334-345. doi: 10.1016/j.neuroimage.2017.08.003
114. Opazo, C., Luza, S., Villemagne, V. L., Volitakis, I., Rowe, C., Barnham, K. J., et al. (2006). Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell 5, 69-79. doi: 10.1111/j.1474-9726.2006.00196.x
115. Ou, P., Tritschler, H. J., and Wolff, S. P. (1995). Thioctic (lipoic) acid: a therapeutic metal-chelating antioxidant? Biochem. Pharmacol. 50, 123-126. doi: 10.1016/0006-2952(95)00116-H
116. Panigrahi, M., Sadguna, Y., Shivakumar, B. R., Kolluri, S. V., Roy, S., Packer, L., et al. (1996). Alpha-Lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res. 717, 184-188. doi: 10.1016/0006-8993(96)00009-1
117. Park, D., Yang, Y. H., Bae, D. K., Lee, S. H., Yang, G., Kyung, J., et al. (2013). Improvement of cognitive function and physical activity of aging mice by human neural stem cells over-expressing choline acetyltransferase. Neurobiol. Aging 34, 2639-2646. doi: 10.1016/j.neurobiolaging.2013.04.026
118. Perry, G., Taddeo, M. A., Petersen, R. B., Castellani, R. J., Harris, P. L., Siedlak, S. L., et al. (2003). Adventiously-bound redox active iron and copper are at the center of oxidative damage in Alzheimer disease. Biometals 16, 77-81. doi: 10.1023/A:1020731021276
119. Peters, D. G., Pollack, A. N., Cheng, K. C., Sun, D., Saido, T., Haaf, M. P., et al. (2018). Dietary lipophilic iron alters amyloidogenesis and microglial morphology in Alzheimer's disease knock-in APP mice. Metallomics 10,426-443. doi: 10.1039/c8mt00004b
120. Plascencia-Villa, G., Ponce, A., Collingwood, J. F., Arellano-Jimenez, M. J., Zhu, X., Rogers, J. T., et al. (2016). High-resolution analytical imaging and electron holography of magnetite particles in amyloid cores of Alzheimer's disease. Sci. Rep. 6:24873. doi: 10.1038/srep24873
121. Pretorius, E., Vermeulen, N., Bester, J., Lipinski, B., and Kell, D. B. (2013). A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicol. Mech. Methods 23, 352-359. doi: 10.3109/15376516.2012.762082
122. Quinn, J. F., Bussiere, J. R., Hammond, R. S., Montine, T. J., Henson, E., Jones, R. E., et al. (2007). Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol. Aging 28, 213-225. doi: 10.1016/j.neurobiolaging.2005.12.014
123. Ramos, P., Santos, A., Pinto, N. R., Mendes, R., Magalhaes, T., and Almeida, A. (2014). Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J. Trace Elem. Med. Biol. 28, 13-17. doi: 10.1016/j.jtemb.2013.08.001
124. Reese, J. P., Dams, J., Winter, Y., Balzer-Geldsetzer, M., Oertel, W. H., and Dodel, R. (2012). Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease. Expert Opin. Pharmacother. 13, 939-958. doi: 10.1517/14656566.2012.677435
125. Reynolds, M. R., Reyes, J. F., Fu, Y., Bigio, E. H., Guillozet-Bongaarts, A. L., Berry, R. W., et al. (2006). Tau nitration occurs at tyrosine 29 in the fibrillar lesions of Alzheimer's disease and other tauopathies. J. Neurosci. 26, 10636-10645. doi: 10.1523/JNEUROSCI.2143-06.2006
126. Ritchie, C. W., Bush, A. I., Mackinnon, A., Macfarlane, S., Mastwyk, M., Macgregor, L., et al. (2003). Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 60, 1685-1691. doi: 10.1001/archneur.60.12.1685
127. Rodrigue, K. M., Haacke, E. M., and Raz, N. (2011). Differential effects of age and history of hypertension on regional brain volumes and iron. Neuroimage 54, 750-759. doi: 10.1016/j.neuroimage.2010.09.068
128. Rogers, J. T., Randall, J. D., Cahill, C. M., Eder, P. S., Huang, X., Gunshin, H., et al. (2002). An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J. Biol. Chem. 277, 45518-45528. doi: 10.1074/jbc.M207435200
129. Seiler, A., Schneider, M., Forster, H., Roth, S., Wirth, E. K., Culmsee, C., et al. (2008). Glutathione peroxidase 4 senses and translates oxidative stress into 12/15-lipoxygenase dependent-and AIF-mediated cell death. Cell Metab. 8, 237-248. doi: 10.1016/j.cmet.2008.07.005
130. Selkoe, D. J. (2012). Preventing Alzheimer's disease. Science 337, 1488-1492. doi: 10.1126/science.1228541
131. Silvestri, L., and Camaschella, C. (2008). A potential pathogenetic role of iron in Alzheimer's disease. J. Cell. Mol. Med. 12, 1548-1550. doi: 10.1111/j.1582-4934.2008.00356.x
132. Smith, M. A., Harris, P. L., Sayre, L. M., and Perry, G. (1997). Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. U.S.A. 94, 9866-9868. doi: 10.1073/pnas.94.18.9866
133. Sripetchwandee, J., Wongjaikam, S., Krintratun, W., Chattipakorn, N., and Chattipakorn, S. C. (2016). A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-beta accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload. Neuroscience 332, 191-202. doi: 10.1016/j.neuroscience.2016.07.003
134. Sternberg, Z., Hu, Z., Sternberg, D., Waseh, S., Quinn, J. F., Wild, K., et al. (2017). Serum hepcidin levels, iron dyshomeostasis and cognitive loss in Alzheimer's disease. Aging Dis. 8, 215-227. doi: 10.14336/AD.2016.0811
135. Suh, J. H., Moreau, R., Heath, S. H., and Hagen, T. M. (2005). Dietary supplementation with (R)-alpha-lipoic acid reverses the age-related accumulation of iron and depletion of antioxidants in the rat cerebral cortex. Redox Rep. 10, 52-60. doi: 10.1179/135100005X21624
136. Tahirbegi, I. B., Pardo, W. A., Alvira, M., Mir, M., and Samitier, J. (2016). Amyloid Abeta 42, a promoter of magnetite nanoparticle formation in Alzheimer's disease. Nanotechnology 27:465102. doi: 10.1088/0957-4484/27/46/465102
137. Tahmasebinia, F., and Emadi, S. (2017). Effect of metal chelators on the aggregation of beta-amyloid peptides in the presence of copper and iron. Biometals 30, 285-293. doi: 10.1007/s10534-017-0005-2
138. Takeda, A. (2004). Essential trace metals and brain function. Yakugaku Zasshi 124, 577-585. doi: 10.1248/yakushi.124.577
139. Telling, N. D., Everett, J., Collingwood, J. F., Dobson, J., Van Der Laan, G., Gallagher, J. J., et al. (2017). Iron biochemistry is correlated with amyloid plaque morphology in an established mouse model of Alzheimer's disease. Cell Chem. Biol. 24, e1203. doi: 10.1016/j.chembiol.2017.07.014
140. Tuo, Q. Z., Lei, P., Jackman, K. A., Li, X. L., Xiong, H., Li, X. L., et al. (2017). Tau-mediated iron export prevents ferroptotic damage after ischemic stroke. Mol. Psychiatry 22, 1520-1530. doi: 10.1038/mp.2017.171
141. Valverde, F., Lopez-Mascaraque, L., and De Carlos, J. A. (1990). Distribution and morphology of Alz-50-immunoreactive cells in the developing visual cortex of kittens. J. Neurocytol. 19, 662-671. doi: 10.1007/BF01188035
142. van Bergen, J. M., Li, X., Hua, J., Schreiner, S. J., Steininger, S. C., Quevenco, F. C., et al. (2016). Colocalization of cerebral iron with amyloid beta in mild cognitive impairment. Sci. Rep. 6:35514. doi: 10.1038/srep35514
143. van Bergen, J. M. G., Li, X., Quevenco, F. C., Gietl, A. F., Treyer, V., Meyer, R., et al. (2018). Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and beta-amyloid as an indicator of cognitive performance at high age. Neuroimage 174, 308-316. doi: 10.1016/j.neuroimage.2018.03.021
144. van de Looij, Y., Ginet, V., Chatagner, A., Toulotte, A., Somm, E., Huppi, P. S., et al. (2014). Lactoferrin during lactation protects the immature hypoxic-ischemic rat brain. Ann. Clin. Transl. Neurol. 1, 955-967. doi: 10.1002/acn3.138
145. van Duijn, S., Bulk, M., Van Duinen, S. G., Nabuurs, R. J. A., Van Buchem, M. A., Van Der Weerd, L., et al. (2017). Cortical iron reflects severity of Alzheimer's disease. J. Alzheimers Dis. 60, 1533-1545. doi: 10.3233/JAD-161143
146. Vela, D. (2018). Hepcidin, an emerging and important player in brain iron homeostasis. J. Transl. Med. 16:25. doi: 10.1186/s12967-018-1399-5
147. Wang, D., Hui, Y., Peng, Y., Tang, L., Jin, J., He, R., et al. (2015). Overexpression of heme oxygenase 1 causes cognitive decline and affects pathways for tauopathy in mice. J. Alzheimers Dis. 43, 519-534. doi: 10.3233/JAD-140567
148. Wang, L., Sato, H., Zhao, S., and Tooyama, I. (2010). Deposition of lactoferrin in fibrillar-type senile plaques in the brains of transgenic mouse models of Alzheimer's disease. Neurosci. Lett. 481, 164-167. doi: 10.1016/j.neulet.2010.06.079
149. Wang, P., and Wang, Z. Y. (2017). Metal ions influx is a double edged sword for the pathogenesis of Alzheimer's disease. Ageing Res. Rev. 35, 265-290. doi: 10.1016/j.arr.2016.10.003
150. Wang, T., Wang, C. Y., Shan, Z. Y., Teng, W. P., and Wang, Z. Y. (2012). Clioquinol reduces zinc accumulation in neuritic plaques and inhibits the amyloidogenic pathway in AbetaPP/PS1 transgenic mouse brain. J. Alzheimers Dis. 29, 549-559. doi: 10.3233/JAD-2011-111874
151. Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., and Zecca, L. (2014). The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13, 1045-1060. doi: 10.1016/S1474-4422(14)70117-6
152. Wong, A., Dukic-Stefanovic, S., Gasic-Milenkovic, J., Schinzel, R., Wiesinger, H., Riederer, P., et al. (2001). Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation end products in murine microglia. Eur. J. Neurosci. 14, 1961-1967. doi: 10.1046/j.0953-816x.2001.01820.x
153. Wright, R. O., and Baccarelli, A. (2007). Metals and neurotoxicology. J. Nutr. 137, 2809-2813. doi: 10.1093/jn/137.12.2809
154. Xie, L., Zheng, W., Xin, N., Xie, J. W., Wang, T., and Wang, Z. Y. (2012). Ebselen inhibits iron-induced tau phosphorylation by attenuating DMT1 up-regulation and cellular iron uptake. Neurochem. Int. 61, 334-340. doi: 10.1016/j.neuint.2012.05.016
155. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., et al. (2016). Ferroptosis: process and function. Cell Death Differ. 23, 369-379. doi: 10.1038/cdd.2015.158
156. Xu, H., Wang, Y., Song, N., Wang, J., Jiang, H., and Xie, J. (2017). New progress on the role of glia in iron metabolism and iron-induced degeneration of dopamine neurons in Parkinson's disease. Front. Mol. Neurosci. 10:455. doi: 10.3389/fnmol.2017.00455
157. Yamamoto, A., Shin, R. W., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., et al. (2002). Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 82, 1137-1147. doi: 10.1046/j.1471-4159.2002.t01-1-01061.x
158. Yang, W. S., and Stockwell, B. R. (2016). Ferroptosis: death by lipid peroxidation. Trends Cell Biol. 26, 165-176. doi: 10.1016/j.tcb.2015.10.014
159. Zecca, L., Stroppolo, A., Gatti, A., Tampellini, D., Toscani, M., Gallorini, M., et al. (2004). The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc. Natl. Acad. Sci. U.S.A. 101, 9843-9848. doi: 10.1073/pnas.0403495101
160. Zhang, B., Gaiteri, C., Bodea, L. G., Wang, Z., Mcelwee, J., Podtelezhnikov, A. A., et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153, 707-720. doi: 10.1016/j.cell.2013.03.030
161. Zhang, W. J., and Frei, B. (2001). Alpha-lipoic acid inhibits TNF-alpha-induced NF-kappaB activation and adhesion molecule expression in human aortic endothelial cells. FASEB J. 15, 2423-2432. doi: 10.1096/fj.01-0260com
162. Zhang, Y. H., Wang, D. W., Xu, S. F., Zhang, S., Fan, Y. G., Yang, Y. Y., et al. (2018). alpha-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol. 14, 535-548. doi: 10.1016/j.redox.2017.11.001
163. Zhao, Y., Raichle, M. E., Wen, J., Benzinger, T. L., Fagan, A. M., Hassenstab, J., et al. (2017). In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Neuroimage 148, 296-304. doi: 10.1016/j.neuroimage.2016.12.026
164. Zhou, Z. D., and Tan, E. K. (2017). Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases. Mol. Neurodegener. 12:75. doi: 10.1186/s13024-017-0218-4